Online inquiry

IVTScrip™ mRNA-Human ACTL6A, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK12463MR)

This product GTTS-WK12463MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ACTL6A protein. This product can be used in FOXN4+ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_004301.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 86
UniProt ID O96019
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ACTL6A, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK12463MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK12193MR IVTScrip™ mRNA-Human ADAM22, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADAM22
GTTS-WK14965MR IVTScrip™ mRNA-Human ANXA7, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANXA7
GTTS-WK21702MR IVTScrip™ mRNA-Human ARHGAP8, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP8
GTTS-WK26758MR IVTScrip™ mRNA-Human ARAP3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARAP3
GTTS-WK19764MR IVTScrip™ mRNA-Human ANXA6, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANXA6
GTTS-WK24993MR IVTScrip™ mRNA-Human ARHGAP29, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARHGAP29
GTTS-WK16798MR IVTScrip™ mRNA-Human APBB1, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APBB1
GTTS-WK23910MR IVTScrip™ mRNA-Human ASGR1, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASGR1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW